BETA DRUGS
Back to Balance Sheet
|
BETA DRUGS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹135 Cr | ₹11 Cr | ₹11 Cr | ₹16 Cr | ₹15 Cr |
What is the latest Total Non-Current Liabilities ratio of BETA DRUGS ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹135 Cr |
| Mar2024 | ₹11 Cr |
| Mar2023 | ₹11 Cr |
| Mar2022 | ₹16 Cr |
| Mar2021 | ₹15 Cr |
How is Total Non-Current Liabilities of BETA DRUGS Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹135 Cr | 1,134.46 | |
| Mar2024 | ₹11 Cr | -3.70 | |
| Mar2023 | ₹11 Cr | -28.62 | |
| Mar2022 | ₹16 Cr | 6.11 | |
| Mar2021 | ₹15 Cr | - | |
Compare Total Non-Current Liabilities of peers of BETA DRUGS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BETA DRUGS | ₹2,375.2 Cr | 0.1% | -14.5% | 13.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹451,339.0 Cr | -2.7% | -3.7% | 20.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹254,068.0 Cr | 3.7% | 15.7% | 51% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,767.0 Cr | -0.8% | 1% | 36.2% | Stock Analytics | |
| CIPLA | ₹111,804.0 Cr | -2.1% | -5.2% | -11.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,113.4 Cr | -0.8% | -0.5% | -9.3% | Stock Analytics | |
BETA DRUGS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BETA DRUGS | 0.1% |
-14.5% |
13.2% |
| SENSEX | -1.8% |
-3.7% |
-5.7% |
You may also like the below Video Courses